A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Latest Information Update: 21 Jun 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-564
- Sponsors Merck Sharp & Dohme Corp.
- 06 May 2024 Results assessing efficacy presented at the 119th Annual Meeting of the American Urological Association
- 02 Feb 2024 Results assessing patient-reported outcomes published in the Oncologist
- 27 Jan 2024 Interim results (data cutoff date: 15 Sep 2023) from the third prespecified interim analysis with a median follow-up of approx. 57 months presented at the 2024 Genitourinary Cancers Symposium